Day: October 26, 2021

Scanfil plc     Interim report     26 October 2021  8.00 am Scanfil Group’s Interim Report for 1 January–30 September 2021: Robust customer demand supported record-high turnover growth. Healthy profitability despite challenges in material availability. July–SeptemberTurnover totalled EUR 167.8 million (7-9 2020: 141.6), an increase of 18.5%. Adjusted operating profit was EUR 9.5 (9.9) million, 5.7% (7.0%) of turnover. Operating profit was EUR 9.5 (21.2) million, 5.7% (15.0%) of turnover. Comparison includes a non-recurring capital gain of EUR 11.4 million from the sale of the Hangzhou factory. Adjusted net profit was EUR 6.8 (7.5) million. Net profit was EUR 5.1 (18.0) million. It was negatively impacted by a non-recurring tax item of EUR 1.7 million. Adjusted earnings per share were EUR 0.10 (0.12), earnings per share were EUR 0.08...

Norsk Hydro ASA posted third-quarter adjusted EBITDA of NOK 7,219 million, compared with NOK 3,100 million for the same quarter last year. Higher all-in metal and alumina prices, in addition to improved upstream volumes contributed positively to adjusted EBITDA, partly offset by higher raw material costs.Strong markets and higher volumes driving record result in Aluminium Metal Robust operations in Bauxite & Alumina 2021 improvement target achieved Lower production volumes mitigated by price area differences in Energy Investments in Recycling and Extrusions supporting Hydro 2025 strategy“I am happy to see our organization delivering record quarter results in a strong aluminium market and reaching our full-year improvement target already during third quarter. Extrusions is delivering ahead of plan, while robust operations in Brazil...

Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +5% (cc¹, +6% USD)Innovative Medicines grew +7% (cc, +8% USD) Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx (+22% cc), Kesimpta (USD 109 million), Jakavi (+26% cc), Zolgensma (+28% cc), Promacta/Revolade (+18% cc) and Kisqali (+27% cc) Sandoz declined -2% (cc, -1% USD), affected by continued pricing pressures. Ex-US sales grew +3% (cc)Q3 core¹ operating income grew +9% (cc, +10% USD)Innovative Medicines grew +13% (cc, +14% USD), due to higher sales and productivity programs Sandoz declined -15% (cc, -13% USD), impacted by gross marginQ3 operating income grew +32% (cc, +34% USD) Q3 net income increased +41% (cc, +43% USD) Q3 free cash flow1 of USD 4.4 billion (+64% USD), with higher operating income, lower payments out of provisions and...

Ad hoc announcement pursuant to Article 53 of the SIX listing rulesMagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020 Kuros expanding MagnetOs range to increase perioperative solutions for surgeonsSCHLIEREN (ZURICH), Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) — Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update on its commercial activities. Direct sales of MagnetOs in the U.S. continued to accelerate in Q3 2021, with a year-to-date increase of 119% over the same period in 2020. Kuros recently showcased new products in the MagnetOs range, including a new 2.5cc unit that is ideal for filling gaps in the spine during posterior cervical fusion procedures, a new formulation of MagnetOs that includes a collagen carrier, and MagnetOs Easypack Putty,...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 26, 2021Idorsia Ltd (SIX: IDIA) today announced its financial results for the third quarter of 2021. Business highlightsFive Idorsia affiliates in key European markets (France, Germany, Italy, Spain, UK) established Daridorexant for the treatment of insomnia under review with US FDA (Food and Drug Administration), EMA (European Medicines Agency), Swissmedic, and Health Canada Clazosentan NDA for the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) under review with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) “SOS-AMI” Phase 3 registration study with selatogrel in suspected acute myocardial infarction (AMI) is recruiting Results for CARE Phase 2b study with cenerimod for systemic lupus erythematosus expected in...

REGULATED INFORMATIONRecruitment ALLOB tibial fracture Phase IIb trial slower than anticipated due to pandemic No statistically significant difference in knee pain reduction between JTA-004, placebo and active comparator, 3 months after treatment in Phase III knee osteoarthritis study First tranche of EUR 8.0 million of the EIB financing received Signing of research evaluation agreement with Implant Therapeutics as well as scientific advisory board appointments latest steps in creating new iMSC platform Runway until end of Q1 2022 as development of iMSC platform acceleratesGosselies, Belgium, 26 October 2021, 7:00 am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces its business update for the third quarter, ended...

Figure 1La Aparecida brownfield area, with observed veins and drill collars.Figure 2The Aurora mine tunnels with rock channel sampling data.TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) — O2Gold Inc. (“O2Gold” or the “Company”) (TSXV: OTGO) is pleased to announce that it has begun drilling at its Aparecida brownfield area. Approximately 5 km from the Aurora tunnels, the Aparecida brownfield has been the site of artisanal production going back more than a century. The systematic exploration of the Aparecida area has indicated an anastomosed pattern, with vein mineralization in close proximity. The Company has documented five gold veins in the area and three veinlets at surface. The Fortaleza Vein, the Company’s first target, has a projected extension of at least 400 meters, and rock channel samples have...

VANCOUVER, British Columbia, Oct. 25, 2021 (GLOBE NEWSWIRE) — Benjamin Hill Mining Corp. (CSE: BNN) (OTCBB: BNNHF) (“BHM” or the “Company”) is pleased to announce the appointment of Sergio Garcia as Chief Financial Officer.   Sergio holds a Master´s Degree from the Western Institute of Business Capacitation in Guadalajara and graduated in Public Accounting from University of Sonora. Mr. Garcia has most recently served as General Accountant for Benjamin Hill Mining Corp’s Mexican operating subsidiary. Prior to that, Sergio performed duties as a Tax Auditor for the Tax Administration Service (SAT), and as a General Accountant for DFK International, in Hermosillo Sonora, and is a former auditor for Sonora Professional. On behalf of the Board of Directors and the Executive Team, the Company would like to thank Paloma Pantoja for her...

SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) — Augmedix, Inc. (Nasdaq: AUGX) (“Augmedix”), a leading provider of virtual medical documentation and live clinical support, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock (“Common Stock”) at a public offering price of $4.00 per share. In addition, Augmedix has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Common Stock at the public offering price less the underwriting discounts and commissions. Gross proceeds from the offering before expenses and underwriting commissions are expected to be $40,000,000.00. The offering is expected to close on or about October 28, 2021 subject to customary closing conditions. Augmedix plans to use the net proceeds it receives from the offering...